S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Amicus Therapeutics, Inc. (FOLD)
Chart Events
Performance Outlook
| Previous Close | 7.42 |
| Open | 7.51 |
| Bid | 7.76 x 3000 |
| Ask | 8.28 x 1300 |
| Day's Range | 7.41 - 7.78 |
| 52 Week Range | 5.91 - 12.63 |
| Volume | |
| Avg. Volume | 3,777,575 |
| Market Cap | 2.162B |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Amicus Therapeutics Receives Notification of PDUFA Date Extensions for AT-GAA
PHILADELPHIA, May 10, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period by 90 days for the Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug Application (NDA) for miglustat, the two components of AT-GAA. The revised PDUFA action dates for miglustat and cipaglucosidase alfa are August 29, 2022 and October 29, 2022, respectively. The Company continues to expect the
- GlobeNewswire
CORRECTING AND REPLACING -- Amicus Therapeutics Announces First Quarter 2022 Financial Results
1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparations for AT-GAA in Pompe Disease Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease Presented at 2022 MDA Conference Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Ami
- GlobeNewswire
Amicus Therapeutics Announces First Quarter 2022 Financial Results
1Q22 Galafold® Revenue Growth of 18.5% to $78.7M New Composition of Matter Patent for Galafold® Strengthens U.S. Patent Protection into 2038 Advancing U.S. and EU Regulatory Reviews and Launch Preparations for AT-GAA in Pompe Disease Positive Long-Term Data from Phase 1/2 Study of AT-GAA in Pompe Disease Presented at 2022 MDA Conference Conference Call and Webcast Today at 8:30 a.m. ET PHILADELPHIA, May 09, 2022 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global b
